Intrarosa in Your 60s and Beyond: What You Need to Know About Vaginal DHEA

Why Genitourinary Syndrome of Menopause Gets Worse in Your 60s

Genitourinary syndrome of menopause (GSM) does not stabilize after menopause. It progresses. In your 40s and early 50s you might notice dryness or occasional discomfort. By your 60s and beyond, the tissue changes are deeper: the vaginal epithelium thins further, the pH rises above 5, lactobacilli decline, and the urethra and bladder lose estrogen-receptor support too.

Population data from the REVIVE survey found that 45 percent of postmenopausal women reported GSM symptoms affecting sexual quality of life, yet fewer than 25 percent had discussed them with a clinician. That silence is common in the 60-plus age group, partly because women assume the symptoms are simply a permanent fact of aging. They are not untreatable.

What is actually happening in vaginal tissue after 60

The vaginal mucosa depends on estrogen and androgens to maintain thickness, lubrication, and elasticity. DHEA (dehydroepiandrosterone), made largely by the adrenal glands and locally by vaginal tissue, is the precursor from which cells convert to both estrogen and testosterone. After menopause, serum DHEA falls to roughly one-fifth of peak reproductive-age levels. This decline continues into the 60s and 70s, which means local vaginal tissue has less raw material to make the hormones it needs for repair.

Why dyspareunia specifically matters at this life stage

Painful intercourse (dyspareunia) is the most commonly reported sexual symptom in women over 60. The SWAN study documented that vulvovaginal dryness and pain with sex affected more than 50 percent of women surveyed at 10 years post-menopause. Beyond sex, GSM in your 60s also drives urinary urgency, recurrent UTIs, and pelvic discomfort with daily activities. These are quality-of-life issues, not vanity complaints.

What Intrarosa Is and How It Works

Intrarosa is a vaginal insert containing 6.5 mg of prasterone, which is synthetic DHEA. You insert one suppository-style ovule vaginally each night at bedtime. The drug is absorbed into vaginal epithelial cells, where local enzymes convert it intracellularly into estradiol and testosterone.

This is the key distinction from standard vaginal estrogen. Prasterone works through intracrine conversion inside the cell. The hormones are used locally and do not accumulate significantly in the bloodstream. In the phase III AMETHYST trial, women using prasterone 6.5 mg nightly showed serum estradiol levels that remained below 5 pg/mL on average, well within the normal postmenopausal reference range of <10-20 pg/mL. Serum testosterone rose slightly but also stayed within the postmenopausal normal range.

The androgen angle most articles miss

Most content about Intrarosa focuses on the estrogen side of the conversion. The androgen side matters just as much for women in their 60s. Vaginal androgen receptors are dense in the submucosa. Testosterone produced intracellularly from DHEA stimulates collagen synthesis, increases tissue thickness, and may contribute to clitoral and labial sensitivity. This dual-pathway action, both estrogenic and androgenic at the tissue level, is what distinguishes prasterone from low-dose vaginal estradiol, which acts only on estrogen receptors.

Women with hypoactive sexual desire disorder (HSDD) alongside GSM may find this androgen component clinically relevant, though prasterone is not formally approved for HSDD. Published sub-analyses from Labrie et al. Suggest improvements in sexual desire scores alongside pain reduction, but these were secondary endpoints.

How it compares to vaginal estrogen

| Treatment | Main mechanism | Serum estrogen rise | Androgen effect | FDA-approved indication | |---|---|---|---|---| | Prasterone (Intrarosa) | Intracrine DHEA conversion | Minimal (<5 pg/mL) | Yes (local testosterone) | Dyspareunia due to menopause | | Vaginal estradiol 10 mcg (Vagifem/Yuvafem) | Direct estrogen receptor activation | Minimal | No | Vaginal atrophy | | Vaginal estradiol ring (Estring) | Sustained estrogen release | Minimal | No | Urogenital atrophy | | Vaginal conjugated estrogen cream (Premarin) | Direct estrogen receptor activation | Low-moderate (dose-dependent) | No | Atrophic vaginitis, dyspareunia | | Ospemifene (Osphena, oral SERM) | Selective ER agonist/antagonist | None (non-hormonal systemic) | No | Dyspareunia, vaginal dryness |

The Clinical Evidence: What the Trials Actually Show

AMETHYST and the phase III program

The FDA approval rests on four randomized, double-blind, placebo-controlled trials collectively involving over 1,000 postmenopausal women. The most cited is AMETHYST (NCT01256684), a 12-week trial in which women receiving prasterone 6.5 mg nightly showed statistically significant improvements in:

• Severity of dyspareunia (most bothersome symptom): mean reduction of 1.42 points on a 3-point scale versus 0.99 for placebo
• Vaginal cell maturation index: significant shift from parabasal to superficial cells
• Vaginal pH: mean reduction of approximately 1.3 units versus 0.7 for placebo
• Self-reported sexual function (secondary endpoint): improvement in the Female Sexual Function Index desire and arousal domains

At 52 weeks in the longer extension arm, benefits were maintained without evidence of tachyphylaxis.

What about women specifically in their 60s and beyond?

The key trials enrolled women aged 40 to 80, with a mean age in the early to mid-50s. Subgroup analyses are not consistently published by decade. This is an evidence gap that deserves honesty. Labrie et al. (2016) enrolled women with a mean of 7.5 years since menopause, so a meaningful portion were in their late 50s and 60s, but decade-specific efficacy data for the 60-plus cohort are not separately published in peer-reviewed literature.

What clinicians extrapolate: the mechanism does not change with advancing age. Vaginal epithelial cells retain the enzymatic machinery to convert DHEA even decades after menopause. The degree of baseline atrophy may be greater in your 60s, which could mean a longer time to full benefit, though no controlled data specifically test this hypothesis.

The Menopause Society position

The Menopause Society (formerly NAMS) 2023 position statement on GSM lists vaginal prasterone as an effective option for dyspareunia due to GSM, recommending it alongside vaginal estrogen as a first-line local hormonal treatment. The statement notes that systemic absorption is low and that prasterone "can be considered in women with a history of breast cancer," with the caveat that data in that population are limited and oncologist consultation is warranted.

Hormone Status and Dosing Considerations in Your 60s

In your 60s, you are almost certainly in established post-menopause. If you had your last period before age 55, you may be 10 or more years past menopause by now. A few clinical points matter at this life stage:

Baseline hormone levels are very low

Serum estradiol in women over 60 who are not using hormone therapy typically runs below 10 pg/mL, often below 5 pg/mL. This means the small rise produced by vaginal prasterone stays within the physiological postmenopausal range. For women who want to confirm this, a baseline serum estradiol level before starting can provide a personal reference point, though the FDA prescribing information does not require it.

One dose fits all (with a caveat)

Intrarosa comes in a single dose: 6.5 mg nightly. There is no dose titration studied in post-marketing trials. Women with very severe atrophy sometimes find the applicator uncomfortable initially. A small amount of water-based lubricant on the applicator tip is permissible and does not affect drug delivery.

Bone health and DHEA

Some observational data suggest DHEA may have modest positive effects on bone mineral density, but this is not an approved indication for prasterone vaginal and should not substitute for dedicated osteoporosis screening or treatment. Women in their 60s should follow USPSTF bone density screening recommendations, regardless of GSM treatment choice.

Thyroid and metabolic context

GSM does not cause thyroid disease, but both are common in women over 60. Hypothyroidism can worsen vaginal dryness independently of estrogen status. If your GSM symptoms seem disproportionate or are not responding to treatment, checking TSH is reasonable. Prasterone has no known interaction with levothyroxine or common metabolic medications.

Pregnancy, Lactation, and Contraception

This section is required for all WomanRx drug articles, even when the answer is brief.

Pregnancy: Prasterone vaginal is not appropriate for use during pregnancy. The drug is indicated exclusively for post-menopausal women. The FDA prescribing label carries no formal pregnancy category under the current labeling system (post-2015 rules), but states the drug should not be used in pregnant women. Animal studies showed fetal sex-organ changes with systemic DHEA exposure, though no human pregnancy data exist for vaginal prasterone.

Lactation: Not applicable. Post-menopausal women do not lactate. If for any reason a perimenopausal or early-menopausal woman who is lactating were to inquire, vaginal prasterone should be avoided given the lack of human lactation data.

Contraception: Not required for post-menopausal women. Prasterone does not restore ovulatory cycles in women whose ovarian reserve is depleted. If a woman is in late perimenopause and uncertain whether she is fully post-menopausal (defined as 12 consecutive months without a period), contraception remains advisable for pregnancy prevention until post-menopausal status is confirmed. Intrarosa is not approved for perimenopausal women.

Who This Is Right For and Who Should Pause

Women in their 60s who are good candidates

• You have moderate-to-severe pain with penetrative sex and want a local, low-systemic-exposure treatment
• You prefer to avoid or cannot take systemic hormone therapy (cardiovascular history, personal preference, prior blood clots)
• You want something with an androgen component for tissue restoration
• You tried over-the-counter lubricants and moisturizers and found them insufficient
• Your primary symptom is dyspareunia; if dryness without sex pain is your only concern, other options may be equally appropriate

Women who should have a careful conversation first

Breast cancer history. This is the most clinically contested area. The Menopause Society 2023 GSM position statement acknowledges that systemic absorption is low but states that "evidence is insufficient to confirm safety" in women with estrogen-receptor-positive breast cancer. A 2022 review in Menopause journal (journals.lww.com) found no published safety data from randomized trials in breast cancer survivors using vaginal prasterone. Your oncologist's input is not optional here.

Women on aromatase inhibitors. If you are taking an aromatase inhibitor (anastrozole, letrozole, exemestane) for breast cancer, adding a DHEA precursor that converts to estrogen locally, even minimally, requires oncologic clearance. Some oncologists approve vaginal prasterone in this context; others do not.

Women with unexplained vaginal bleeding. Any postmenopausal bleeding requires evaluation before starting any vaginal hormonal product.

Women with liver disease. Steroid metabolism is hepatic. Significant liver impairment could theoretically alter DHEA metabolism, though no specific pharmacokinetic studies in women with liver disease are published for the vaginal route.

Women for whom other options may be preferred first

• Mild GSM symptoms: a non-hormonal vaginal moisturizer used three times weekly (such as Replens or hyaluronic acid-based products) is a reasonable first step
• Women who want systemic menopause relief alongside GSM treatment: systemic HRT addresses hot flushes and GSM simultaneously; vaginal prasterone does not treat vasomotor symptoms
• Women with predominantly urinary symptoms: vaginal estrogen has more published evidence for recurrent UTI prevention than prasterone specifically

Starting Intrarosa: Practical Guide for Women Over 60

The first 12 weeks

Insert one prasterone 6.5 mg ovule vaginally each night before bed. The reusable applicator is included. You do not need to use it at a fixed time, but nightly consistency helps. Expect:

• Week 1 to 4: Possible mild vaginal discharge or wetness from the suppository base melting. This is not infection. Some women notice slight irritation initially as atrophic tissue adjusts.
• Week 4 to 8: Most women begin noticing improved lubrication with arousal and less discomfort with touch.
• Week 12: The primary clinical endpoint in trials. Reassess symptoms here.

If you see no change at 12 weeks, a conversation with your clinician about alternatives (vaginal estrogen, ospemifene, pelvic floor physical therapy) is warranted.

Pelvic floor physical therapy as an adjunct

For women in their 60s, pelvic floor muscle tension and scar tissue from prior deliveries or surgery can compound GSM-related dyspareunia. Prasterone addresses the tissue hormonal deficit. It does not release hypertonic pelvic floor muscles. A pelvic floor physical therapist evaluation alongside starting Intrarosa is clinically sensible for women with moderate-to-severe dyspareunia, particularly if the pain has been present for years.

Monitoring

No routine serum hormone monitoring is required by the FDA label. Some clinicians check baseline and 12-week serum DHEAS, estradiol, and testosterone in women who are concerned about systemic exposure. Given the data showing minimal serum rise, this is reassurance monitoring rather than safety monitoring. Annual gynecologic exam with attention to vaginal tissue health is standard of care for any woman using a vaginal hormonal product long-term.

Side Effects and What to Watch For

In the AMETHYST trial, the most common adverse event was vaginal discharge, reported by approximately 6 percent of prasterone users versus 1 percent of placebo users. This is the applicator-melting discharge, not infection-related. Other adverse events occurred at similar rates in prasterone and placebo arms:

• Abnormal Pap smear: similar rates, no causal relationship established
• Urinary tract infection: similar rates between groups
• Vaginal yeast infection: similar rates between groups

No serious systemic adverse events were attributed to prasterone in the 12-week or 52-week data. Serum DHEAS rose as expected (the drug is absorbed and converted), but estradiol and testosterone remained within postmenopausal reference ranges.

One practical note: some women over 60 with severe atrophy find insertion mildly uncomfortable at first. Using the applicator rather than a finger typically improves placement and reduces discomfort. If insertional pain from the applicator itself is a problem, ask your clinician about digital insertion instead.

The Evidence Gap: What We Still Do Not Know

Women have been under-represented in many clinical trials, and the prasterone data, while adequate for FDA approval, leave specific questions unanswered for the 60-plus age group:

1. Decade-specific efficacy data have not been published. The trials enrolled women up to age 80, but subgroup results by 60-69 and 70-plus are not in the public domain.
2. Long-term data beyond 52 weeks are limited. Women in their 60s may use this drug for a decade or more. The 52-week extension provides reassurance, but 5- or 10-year safety data do not exist.
3. Breast cancer survivor safety has not been tested in a randomized trial. All guidance in this population is expert opinion or extrapolation.
4. Comparative effectiveness versus vaginal estradiol at the same duration and tissue-severity level has not been studied head-to-head in a large registered trial.

These are not reasons to avoid prasterone if it suits your situation. They are reasons to have an informed conversation with your clinician rather than assuming published approval means all questions are answered.